Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
15 hedge funds and large institutions have $184K invested in Iterum Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
1.67% less ownership
Funds ownership: 3.41% → 1.74% (-1.7%)
12% less funds holding
Funds holding: 17 → 15 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
88% less capital invested
Capital invested by funds: $1.52M → $184K (-$1.33M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$32.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$18.6K |
| 3 |
Renaissance Technologies
New York
|
+$3.93K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$1.14K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.13M |
| 2 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
-$214K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$51 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9 |
ITRM Hedge Fund Activity: Q3 2023 in Review
15 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q3 2023, worth a combined $184K — down 88% from $1.52M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ITRM and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, adding an estimated $32.8K. The largest seller was Sabby Management, exiting entirely with an estimated $1.13M sold.
- 15 institutional investors held Iterum Therapeutics (ITRM) as of Q3 2023, down from 17 in Q2 2023.
- Funds reported $184K of Iterum Therapeutics stock for Q3 2023, down 88% quarter-over-quarter.
- 1 fund opened new Iterum Therapeutics positions in Q3 2023 and 3 closed out, a net change of -2 holders.
- The largest Iterum Therapeutics buyer in Q3 2023 was Susquehanna International Group, an estimated $32.8K added.
- The largest Iterum Therapeutics seller in Q3 2023 was Sabby Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q3 2023.